Successful Therapy Must Eradicate Cancer Stem Cells

Despite significant improvements in cancer therapy, tumor recurrence is frequent and can be due to a variety of mechanisms, including the evolution of resistance and tumor progression. Cancer stem cells have been postulated to maintain tumor growth similar to normal stem cells maintaining tissue homeostasis. Recently, the existence of these malignant stem cells has been proven for hematological as well as some solid tumors. Tumor stem cells are not targeted by standard therapy and might be responsible for treatment failure and tumor recurrence in many patients. We designed a simple mathematical model to demonstrate the importance of eliminating tumor stem cells. We explored different therapeutic scenarios to illustrate the properties required from novel therapeutic agents for successful tumor treatment. We show that successful therapy must eradicate tumor stem cells.

[1]  K. Shimokata,et al.  Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[3]  Stefan N. Constantinescu,et al.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera , 2005, Nature.

[4]  Michael C Mackey,et al.  A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia. , 2005, Journal of theoretical biology.

[5]  M. Tallman.  Differentiating therapy in acute myeloid leukemia. , 1996, Leukemia.

[6]  P Guttorp,et al.  Behavior of hematopoietic stem cells in a large animal. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. V. van Dongen,et al.  The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. , 2005, Blood.

[8]  M. Nowak,et al.  Linear Model of Colon Cancer Initiation , 2004, Cell cycle.

[9]  Goldie Jh,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983 .

[10]  M. Nowak,et al.  Dynamics of cancer progression , 2004, Nature Reviews Cancer.

[11]  F. Taddei,et al.  Role of mutator alleles in adaptive evolution , 1997, Nature.

[12]  H. Kantarjian,et al.  The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase , 2004, Cancer.

[13]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.

[14]  Mats O. Karlsson,et al.  Mechanistic Models for Myelosuppression , 2003, Investigational New Drugs.

[15]  Larry Norton,et al.  Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. , 2005, The oncologist.

[16]  Steven A Frank,et al.  Somatic selection for and against cancer. , 2003, Journal of theoretical biology.

[17]  Z. Estrov,et al.  AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells , 2005, Cancer.

[18]  L. Norton,et al.  Predicting the course of Gompertzian growth , 1976, Nature.

[19]  Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. , 1999, Blood.

[20]  F. Mandelli,et al.  AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. , 1996, Blood.

[21]  P Guttorp,et al.  Evidence for the maintenance of hematopoiesis in a large animal by the sequential activation of stem-cell clones. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Vincent,et al.  An evolutionary model of carcinogenesis. , 2003, Cancer research.

[23]  I. Pastan,et al.  P-glycoprotein-mediated multidrug resistance in normal and neoplastic hematopoietic cells , 1994, Annals of Hematology.

[24]  Martin A. Nowak,et al.  Dynamics of chronic myeloid leukaemia , 2005, Nature.

[25]  Jorge Cortes,et al.  Clonal evolution in chronic myelogenous leukemia. , 2004, Hematology/oncology clinics of North America.

[26]  S. Forman,et al.  Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli , 2005, Leukemia.

[27]  J. Panetta,et al.  A mathematical model of drug resistance: heterogeneous tumors. , 1998, Mathematical biosciences.

[28]  T. Holyoake,et al.  Punish the parent not the progeny. , 2005, Blood.

[29]  Nordling Co.  A New Theory on the Cancer-inducing Mechanism , 1953 .

[30]  A. Tefferi,et al.  Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. , 2004, Leukemia research.

[31]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  John Carl Panetta,et al.  A mechanistic mathematical model of temozolomide myelosuppression in children with high-grade gliomas. , 2003, Mathematical biosciences.

[33]  P. Armitage,et al.  A Two-stage Theory of Carcinogenesis in Relation to the Age Distribution of Human Cancer , 1957, British Journal of Cancer.

[34]  Zeljko Bajzer,et al.  Mathematical modeling of cancer radiovirotherapy. , 2006, Mathematical biosciences.

[35]  M. Tallman,et al.  Long-term follow-up and potential for cure in acute promyelocytic leukaemia. , 2003, Best practice & research. Clinical haematology.

[36]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[37]  M. Deininger,et al.  Can we afford to let sleeping dogs lie? , 2005, Blood.

[38]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[39]  A. Sartorelli,et al.  Combination of all-trans retinoic acid and lithium chloride surmounts a retinoid differentiation block induced by expression of Scl and Rbtn2 transcription factors in myeloid leukemia cells. , 2004, Leukemia research.

[40]  I. Roninson,et al.  Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells , 1991, Cell.

[41]  J. C. FISHER,et al.  Multiple-Mutation Theory of Carcinogenesis , 1958, Nature.

[42]  H. Kantarjian,et al.  Discontinuation of imatinib therapy after achieving a molecular response. , 2004, Blood.

[43]  H. Kantarjian,et al.  Sudden onset of the blastic phase of chronic myelogenous leukemia , 2003, Cancer.

[44]  J. Goldie,et al.  Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983, Cancer treatment reports.

[45]  M. Nowak,et al.  The linear process of somatic evolution , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  H. Nakauchi,et al.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype , 2001, Nature Medicine.

[47]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[48]  U. Germing,et al.  Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. , 2004, Blood.

[49]  E. Kandel,et al.  Proceedings of the National Academy of Sciences of the United States of America. Annual subject and author indexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[50]  L. Nunney,et al.  Lineage selection and the evolution of multistage carcinogenesis , 1999, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[51]  J. Dick,et al.  Primitive human hematopoietic cells are enriched in cord blood compared with adult bone marrow or mobilized peripheral blood as measured by the quantitative in vivo SCID-repopulating cell assay. , 1997, Blood.

[52]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[53]  A. Hochhaus,et al.  Clinical resistance to imatinib: mechanisms and implications. , 2004, Hematology/oncology clinics of North America.

[54]  J. Dick,et al.  Breast cancer stem cells revealed , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Dick,et al.  Cancer stem cells: lessons from leukemia. , 2005, Trends in cell biology.

[56]  L. Sabatier,et al.  Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells , 2004, Oncogene.

[57]  Alexander Levitzki,et al.  PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases. , 2004, Cytokine & growth factor reviews.

[58]  Martin A Nowak,et al.  Evolutionary dynamics of escape from biomedical intervention , 2003, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[59]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[60]  Peter Guttorp,et al.  Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. , 2002, Blood.

[61]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[62]  K. Bunting.  ABC Transporters as Phenotypic Markers and Functional Regulators of Stem Cells , 2002, Stem cells.

[63]  J Bélair,et al.  Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis. , 1998, Journal of theoretical biology.

[64]  P. Armitage,et al.  The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.

[65]  S H Moolgavkar,et al.  Mutation and cancer: a model for human carcinogenesis. , 1981, Journal of the National Cancer Institute.

[66]  Y. Honma,et al.  Differentiation of Human Myeloid Leukemia Cells by Plant Redifferentiation-inducing Hormones , 2002, Leukemia & lymphoma.

[67]  M. Nowak,et al.  Evolution of resistance to cancer therapy. , 2006, Current pharmaceutical design.

[68]  D. Steinemann,et al.  BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. , 2005, Cancer genetics and cytogenetics.

[69]  B. Sorrentino,et al.  Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia , 2005, Leukemia.

[70]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[71]  J. Karp,et al.  Timed sequential therapy of acute myelogenous leukemia in adults: a phase II study of retinoids in combination with the sequential administration of cytosine arabinoside, idarubicin and etoposide. , 2003, Leukemia research.

[72]  J. Dick,et al.  Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.